BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ponsegromab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ponsegromab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06989437-642@assetmemo.bio
DTSTAMP:20261121T005614Z
DTSTART;VALUE=DATE:20280123
DTEND;VALUE=DATE:20280124
SUMMARY:Ponsegromab: Phase 2/3 readout est. (NCT06989437)
DESCRIPTION:Ponsegromab\, phase 2/3.\nStudy: A Study to Learn About the Med
 icine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread a
 nd Caused Significant Body Weight Loss and Fatigue\nEstimated primary comp
 letion: 23 January 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ponsegromab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06989437
URL:https://assetmemo.bio/drug/ponsegromab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07663630-642@assetmemo.bio
DTSTAMP:20261121T005614Z
DTSTART;VALUE=DATE:20280506
DTEND;VALUE=DATE:20280507
SUMMARY:Ponsegromab: Phase 1 readout est. (NCT07663630)
DESCRIPTION:Ponsegromab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy to Learn About the Study Medicine Called Ponsegromab in Adults With L
 ung Cancer-Associated Significant Body Weight Loss\nEstimated primary comp
 letion: 6 May 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 onsegromab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07663630
URL:https://assetmemo.bio/drug/ponsegromab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
